MW 1155.3 Da, Purity >99%. Potent HMG-CoA reductase inhibitor (IC50 = 8 nM). Metabolised by CYP3A4. Able to reduce circulating LDL-C through inhibition of cholesterol biosynthesis and inducing expression of LDL receptors.
134523-03-8
> 99%
Solid
1155.3 Da
C66H68CaF2N4O10
60822
Synthetic
3 hydroxy 3 methylglutaryl CoA reductase, 3 hydroxymethylglutaryl CoA reductase, 3-hydroxy-3-methylglutaryl CoA reductase (NADPH), 3-hydroxy-3-methylglutaryl-coenzyme A reductase, 3H3M, A830040C14Rik, ABC 31, ABC member 16, MDR/TAP subfamily, ABC16, ABCB1, ABCBB_HUMAN, ABCC 3, AI838772, APOPAIN, ATP binding cassette sub family B (MDR/TAP) member 11, ATP binding cassette sub family C (CFTR/MRP) member 3, ATP-binding cassette sub-family B member 11, ATP-binding cassette sub-family C member 3, AW493413, Apoptotic protease Mch-3, Atherosclerosis, susceptibility to, included, BRIC2, BXR, Bile salt export pump, Bsep, CASP3_HUMAN, CASP7_HUMAN, CC3, CMH-1, CMOAT 2, CPP-32, CPP32B, Canalicular multispecific organic anion transporter 2, Canicular multispecific organic anion transporter, Casp3a, Caspase 3, apoptosis-related cysteine peptidase, Caspase 3, apoptosis-related cysteine protease, Caspase 3, apoptosis-related cysteine protease a, Caspase 7, Caspase 7 apoptosis related cysteine peptidase, Caspase-3, Caspase-3 subunit p12, Caspase-7 subunit p11, Cysteine protease CPP32, DKFZp686N23123, EC 3.4.22.56, ER, ER-alpha, ER-beta, ERR a, ERR-alpha, ERR1 protein, ERR1_HUMAN, ER[a], ER[b], ESR, ESR B, ESR BETA, ESR1_HUMAN, ESRA, ESRL 1, ESRR A, EST90757, ESTR B, Era, Erb, Erb2, Estr, Estra, Estradiol Receptor alpha, Estradiol Receptor beta, Estradiol receptor, Estrogen Receptor 1, Estrogen Receptor 2, Estrogen receptor, Estrogen receptor 1 (alpha), Estrogen receptor 2 (ER beta), Estrogen receptor 2 ER beta, Estrogen receptor alpha, Estrogen receptor beta 4, Estrogen receptor related 1, Estrogen receptor-like 1, Estrogen resistance, included, Estrogen-related receptor alpha, Estrra, FLJ11090, GCCR, GCRST, GCR_HUMAN, GR, Glucocorticoid receptor, Grl1, HDL cholesterol, augmented response of, to hormone replacement, included, HMDH_HUMAN, HMG CoAR, HMG-CoA reductase, Hydroxymethylglutaryl CoA reductase, ICE-LAP3, ICE-like apoptotic protease 3, ICE3, IMD42, LDLCQ3, LICE, LICE2, Liver-specific organic anion transporter 1, MCH3, MGC103269, MGC104252, MGC112732, MGC129539, MLP 2, MOAT-D, MRP3_HUMAN, Multi-specific organic anion transporter D, Multidrug resistance associated protein, Multidrug resistance-associated protein 3, Multispecific organic anion tranporter D, Myocardial infarction, susceptibility to, included, NF-E2-related factor 2, NF2L2_HUMAN, NR1F3, NR1I2_HUMAN, NR3A1, NR3A2, NR3B1, NRF2, Nfe2l2, Nuclear factor, Nuclear factor (erythroid derived 2) like 2, Nuclear factor erythroid 2-related factor 2, Nuclear factor erythroid derived 2 like 2, Nuclear receptor ROR-gamma, Nuclear receptor RZR-gamma, Nuclear receptor subfamily 1 group F member 3, Nuclear receptor subfamily 1 group I member 2, Nuclear receptor subfamily 3 group A member 1, Nuclear receptor subfamily 3 group A member 2, Nuclear receptor subfamily 3 group B member 1, Nuclear receptor subfamily 3 group C member 1, OATP-2, OATP-C, ONR 1, OTTHUMP00000017718, OTTHUMP00000017719, OTTHUMP00000165052, OTTHUMP00000165053, OTTHUMP00000165054, OTTHUMP00000215173, OTTHUMP00000215174, OTTHUMP00000215175, Orphan nuclear receptor PAR 1, Orphan nuclear receptor PXR, PAR, PAR q, PARP cleavage protease, PFIC 2, PGY4, PRR, Pregnane X receptor, Procaspase3, Protein Yama, RAR related orphan nuclear receptor variant 2, RAR related orphan receptor C, isoform a, RAR related orphan receptor gamma, RAR-related orphan receptor C, RNESTROR, RORG_HUMAN, RP24-311F12.2, RZR GAMMA, RZRG, Retinoic acid binding receptor gamma, Retinoid-related orphan receptor-gamma, Rorc, SCA-1, SCAN1, SLC21A6, SLCO1B1, SO1B1_HUMAN, SREBP cleavage activity 1, SXR, Sister of P glycoprotein, Sodium-independent organic anion-transporting polypeptide 2, Solute carrier family 21 member 6, Solute carrier organic anion transporter family member 1B1, Spgp, Steroid and xenobiotic receptor, Steroid hormone receptor ERR1, TOR, TYDP, TYDP1_HUMAN, Tyr-DNA phosphodiesterase 1, Tyrosyl-DNA phosphodiesterase 1, Yama, Yama protein, erythroid derived 2, estrogen receptor related receptor alpha, glucocorticoid nuclear receptor variant 1, hERR1, like 2, mldy, nr3c1, nuclear factor erythroid 2 like 2, nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor), pregnane X nuclear receptor variant 2, progressive familial intrahepatic cholestasis 2
MW 1155.3 Da, Purity >99%. Potent HMG-CoA reductase inhibitor (IC50 = 8 nM). Metabolised by CYP3A4. Able to reduce circulating LDL-C through inhibition of cholesterol biosynthesis and inducing expression of LDL receptors.
134523-03-8
> 99%
Solid
1155.3 Da
C66H68CaF2N4O10
60822
Synthetic
Soluble in DMSO to 100 mM.
Atorvastatin calcium
Potent HMG-CoA reductase inhibitor (IC50 = 8 nM). Metabolised by CYP3A4. Able to reduce circulating LDL-C through inhibition of cholesterol biosynthesis and inducing expression of LDL receptors.
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)[O-])O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4.CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)[O-])O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4.[Ca+2]
CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)[O-])O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4.CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)[O-])O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4.[Ca+2]
InChI=1S/2C33H35FN2O5.Ca/c2*1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40;/h2*3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40);/q;;+2/p-2/t2*26-,27-;/m11./s1
FQCKMBLVYCEXJB-MNSAWQCASA-L
calcium;(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoate
Ambient - Can Ship with Ice
-20°C
-20°C
It is important to note that this product is reported to be light sensitive, Store in the dark, Store under desiccating conditions
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
2D chemical structure image of ab141083, Atorvastatin hemicalcium salt, HMG-CoA reductase inhibitor
Anti-Cytochrome C antibody ab90529 staining cytochrome C in HepG2 cells treated with atorvastatin hemicalcium salt (ab141083), by ICC/IF. Increase of cytochrome C expression correlates with increased concentration of atorvastatin hemicalcium salt, as described in literature.
The cells were incubated at 37°C for 4 hours in media containing different concentrations of ab141083 (atorvastatin hemicalcium salt) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with Anti-Cytochrome C antibody ab90529 (1 µg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 anti-rabbit polyclonal antibody (Goat Anti-Rabbit IgG H&L (DyLight® 488) preadsorbed ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com